Ayala Pharmaceuticals, Inc. (AYLA)

NASDAQ: AYLA · IEX Real-Time Price · USD
1.06
-0.03 (-2.75%)
Jul 1, 2022 12:26 PM EDT - Market open

Company Description

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers.

The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations.

It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors.

Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma.

The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals Logo
Country United States
Founded 2017
IPO Date May 8, 2020
Industry Biotechnology
Sector Health Care
Employees 35

Contact Details

Address:
4 Oppenheimer Street
Rehovot 7670104
Israel
Phone 857 444 0553
Website ayalapharma.com

Stock Details

Ticker Symbol AYLA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $15.00
CIK Code 1797336
CUSIP Number 05465V108
ISIN Number US05465V1089
SIC Code 2836

Key Executives

Name Position
Dr. Roni Mamluk M.D., Ph.D. President, Chief Executive Officer and Director
Yossi Maimon CPA, M.B.A., CPA, MBA Chief Financial Officer, Secretary and Treasurer
Dr. Gary B. Gordon M.D., Ph.D. Chief Medical Officer
Irit Klipper Avni M.A. Vice President of Human Resources
Dana Gelbaum M.B.A., M.Sc. Chief Business Officer

Latest SEC Filings

Date Type Title
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
Jun 15, 2022 4 Statement of changes in beneficial ownership of securities
Jun 14, 2022 8-K Current report
Jun 3, 2022 8-K Current report
May 16, 2022 4 Statement of changes in beneficial ownership of securities
May 16, 2022 4 Statement of changes in beneficial ownership of securities
May 16, 2022 4 Statement of changes in beneficial ownership of securities
May 16, 2022 10-Q Quarterly report [Sections 13 or 15(d)]